Q-omics provides the consensus-scored KRT43P profile across patient tissues and cancer cell-line models. KRT43P expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, KRT43P is differentially expressed in 6, with the highest sampling consensus in HNSC. Additionally, KRT43P RNA expression shows 6,224 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LIHC, HNSC, and STAD as cancer lineages where KRT43P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT43P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT43P survival associations across molecular data types. KRT43P RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT43P RNA expression–survival associations across cancer types. High KRT43P expression shows unfavorable associations in LIHC, CESC, GBM, THYM, KIRC and HNSC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for KRT43P RNA expression.
This table summarizes KRT43P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for KRT43P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT43P shows lower tumor expression in HNSC, BRCA and ESCA and higher tumor expression in COAD, LUSC and KIRP. The HNSC box plot shows higher KRT43P RNA expression in normal versus tumor tissue (log2 FC = −0.222, t-test p = .008).
This table shows molecular features associated with KRT43P in patient tissues and cancer cell lines. In patient samples, KRT43P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
